A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer

SIMPLE SUMMARY: Despite early utilization of new hormonal agents (NHA, i.e., abiraterone, enzalutamide and apalutamide) for combined androgen deprivation therapy (ADT) for metastatic prostate cancer, increasingly more men are dying from this disease. While continued development of new drugs is neede...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingsong, Gallaher, Jill, Cunningham, Jessica J., Choi, Jung W., Ionescu, Filip, Chatwal, Monica S., Jain, Rohit, Kim, Youngchul, Wang, Liang, Brown, Joel S., Anderson, Alexander R., Gatenby, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656891/
https://www.ncbi.nlm.nih.gov/pubmed/36358643
http://dx.doi.org/10.3390/cancers14215225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656891/
https://www.ncbi.nlm.nih.gov/pubmed/36358643
http://dx.doi.org/10.3390/cancers14215225

Ejemplares similares